Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A 4 analog: Protective mechanisms and long-term effects on neurological recovery.

Autor: Hawkins KE; Department of Neuroscience McKnight Brain Institute University of Florida Gainesville FL USA., DeMars KM; Department of Neuroscience McKnight Brain Institute University of Florida Gainesville FL USA., Alexander JC; Department of Anesthesiology University of Florida Gainesville FL USA., de Leon LG; Department of Neuroscience McKnight Brain Institute University of Florida Gainesville FL USA., Pacheco SC; Department of Neuroscience McKnight Brain Institute University of Florida Gainesville FL USA., Graves C; Department of Oral Biology University of Florida Gainesville FL USA., Yang C; Department of Neuroscience McKnight Brain Institute University of Florida Gainesville FL USA., McCrea AO; Department of Neuroscience McKnight Brain Institute University of Florida Gainesville FL USA., Frankowski JC; Interdepartmental Neuroscience Program University of California Irvine CA USA., Garrett TJ; Department of Pathology, Immunology and Laboratory Medicine University of Florida Gainesville FL USA., Febo M; Department of Psychiatry University of Florida Gainesville FL USA., Candelario-Jalil E; Department of Neuroscience McKnight Brain Institute University of Florida Gainesville FL USA.
Jazyk: angličtina
Zdroj: Brain and behavior [Brain Behav] 2017 Apr 12; Vol. 7 (5), pp. e00688. Date of Electronic Publication: 2017 Apr 12 (Print Publication: 2017).
DOI: 10.1002/brb3.688
Abstrakt: Background: Resolution of inflammation is an emerging new strategy to reduce damage following ischemic stroke. Lipoxin A 4 (LXA 4 ) is an anti-inflammatory, pro-resolution lipid mediator that reduces neuroinflammation in stroke. Since LXA 4 is rapidly inactivated, potent analogs have been synthesized, including BML-111. We hypothesized that post-ischemic, intravenous treatment with BML-111 for 1 week would provide neuroprotection and reduce neurobehavioral deficits at 4 weeks after ischemic stroke in rats. Additionally, we investigated the potential protective mechanisms of BML-111 on the post-stroke molecular and cellular profile.
Methods: A total of 133 male Sprague-Dawley rats were subjected to 90 min of transient middle cerebral artery occlusion (MCAO) and BML-111 administration was started at the time of reperfusion. Two methods of week-long BML-111 intravenous administration were tested: continuous infusion via ALZET ® osmotic pumps (1.25 and 3.75 μg μl -1  hr -1 ), or freshly prepared daily single injections (0.3, 1, and 3 mg/kg). We report for the first time on the stability of BML-111 and characterized an optimal dose and a dosing schedule for the administration of BML-111.
Results: One week of BML-111 intravenous injections did not reduce infarct size or improve behavioral deficits 4 weeks after ischemic stroke. However, post-ischemic treatment with BML-111 did elicit early protective effects as demonstrated by a significant reduction in infarct volume and improved sensorimotor function at 1 week after stroke. This protection was associated with reduced pro-inflammatory cytokine and chemokine levels, decreased M1 CD40+ macrophages, and increased alternatively activated, anti-inflammatory M2 microglia/macrophage cell populations in the post-ischemic brain.
Conclusion: These data suggest that targeting the endogenous LXA 4 pathway could be a promising therapeutic strategy for the treatment of ischemic stroke. More work is necessary to determine whether a different dosing regimen or more stable LXA 4 analogs could confer long-term protection.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje